Epigenetic Modifier: Unveiling the Dual Nature of MLL4
The world of cancer research is abuzz with the discovery of a unique epigenetic modifier, MLL4, which has been found to play a dual role in cancer development. This modifier, named for its position in a family of similar proteins, has been a subject of intrigue for scientists at Rockefeller University, particularly Robert Roeder and his team.
In a groundbreaking study published in Molecular Cell, Roeder and his colleagues, including structural biologist Jianfeng Sun, have revealed surprising new characteristics of MLL4. This research not only expands our understanding of MLL4's functions but also sheds light on its complex relationship with a tumor-suppressing protein, p53.
The Guardian of the Genome
MLL4 is a histone lysine methyltransferase, one of six members of the mixed-lineage leukemia (MLL) family. It plays a crucial role in methylating histone 3 at lysine 4 (H3K4), which regulates gene activation. MLL4's importance is underscored by its presence in virtually all mammalian cells and its status as the largest protein in the mammalian nucleus.
In MLL-rearranged leukemias, MLL4 acts as a protector, shielding leukemia cells from oxidative and genotoxic stress and maintaining leukemia stem cells in an undifferentiated state. However, in solid tumors, it forms a synergistic relationship with p53, a transcription factor known as 'the guardian of the genome.'
Unraveling the Molecular Mechanics
The study's first author, Jianfeng Sun, realized that understanding MLL4's structure could provide crucial insights into its dual functions. By employing cryo-EM imaging, genetics, and an in vitro transcription system, the team revealed the first complete model of MLL4's nine subunits, five of which are unique.
Sun's findings showed that MLL4 anchors itself to the nucleosome with rigid structures but possesses a flexible 'arm' to tag histones with methylation markers, activating gene expression. Additionally, the N-terminal region of MLL4 folds back onto the C-terminal region, forming a unique structural architecture essential for its transcriptional coactivation function.
A Surprising Discovery
The most intriguing finding was that MLL4's primary function in gene transcription is through histone 3 methylation, yet it is also essential for p53 target gene transcription as a direct co-activator. This revelation highlights a new and unexpected role for MLL4 in cancer.
Roeder emphasizes the significance of this discovery, stating that it demonstrates MLL4's previously unknown functions in transcription. As a key regulator of gene activity, understanding MLL4's mechanisms is crucial, especially in cancer cells.
Future Directions
The research team's next step is to investigate MLL4's interactions with leukemia transcription factors, parallel to p53, to gain a deeper understanding of its context-dependent functions in cancer. Roeder's long-term goal is to comprehend how MLL4 supports leukemia-associated transcriptional programs in one context and tumor suppression in another.
This study not only unveils the dual nature of MLL4 but also opens up new avenues for cancer research, offering a more comprehensive understanding of epigenetic modifiers and their complex roles in cancer development and progression.
